Correlation Between Objective Evaluation Result of Nasal Congestion and Life Quality in Patients with Acute Rhinosinusitis

Mengko, Steward K.; Soemantri, Roestiniadi D.; Juniati, Sri Herawati

doi:10.1007/s12070-018-1333-4

Cited by 5 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Participants in this study were children diagnosed with rhinosinusitis. Participant's inclusion criteria included children aged 3–18 years [ 16 , 17 ], diagnosed with chronic rhinosinusitis according to the European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) [ 18 , 19 ], and reactive skin prick test results using HDM allergen. The exclusion criteria for the participants included abnormal shapes in the anatomy of the nose and paranasal sinuses, patients diagnosed with cancer, having an autoimmune disease, being diagnosed with cerebral palsy, and Down syndrome.…”

Section: Methodsmentioning

confidence: 99%

The role of house dust mite immunotherapy in Indonesian children with chronic rhinosinusitis allergy: A randomized control trial

Putera

Hikmah

Endaryanto

et al. 2021

Heliyon

View full text Add to dashboard Cite

Background Chronic rhinosinusitis allergy (CRA) is a disease that is commonly found in children and is mostly caused by allergy to house dust mites (HDM). The use of HDM immunotherapy can be considered in children with allergies. Objectives Analyzing the impact of mite immunotherapy on disease burden in Indonesian children with CRA. Methods A randomized control trial study was conducted to participants in 2 groups, namely the immunotherapy group (n = 25) and the non-immunotherapy group (n = 25). Participants were given HDM immunotherapy for 14 weeks, which was given once per week. Participants during therapy were evaluated for rhinosinusitis symptoms and measured their immunity status (specific IgE), sleep quality (SDSC), quality of life (SN5), and family coping (F-COPES) pre-post therapy. Statistical analysis used in this study included paired t-test, Wilcoxon test, independent t-test, or Mann Whitney test with p < 0.05. Results The value of specific IgE in the immunotherapy group was 4.12 ± 7.75 kU/l (pre-test) and 1.52 ± 2.42 kU/l (post-test; p < 0.001), while in the non-immunotherapy group was 1.47 ± 3.28 kU/l (pre-test) and 1.18 ± 2.81 kU/l (post-test; p = 0.317). The SDSC value in the immunotherapy group was 42.16 ± 2.75 (pre-test) and 30.32 ± 3.22 (post-test; p < 0.001), while in the non-immunotherapy group was 41.92 ± 2.75 (pre-test) and 41.84 ± 2.87 (post-test; p = 0.987). The F-COPES value in the immunotherapy group was 101.56 ± 5.78 (pre-test) and 105.20 ± 4.31 (post-test; p = 0.015), while in the non-immunotherapy group was 100.36 ± 9.63 (pre-test) and 99.96 ± 9.98 (post-test; p = 0.224). The SN-5 value in the immunotherapy group was 30.04 ± 2.78 (pre-test) and 11.00 ± 2.33 (post-test; p < 0.001), while in the non-immunotherapy group was 30.04 ± 2.78 (pre-test) and 30.04 ± 2.78 (post-test; p = 0.767). There was a significant comparison between the immunotherapy group and the non-immunotherapy group on the specific IgE ( p = 0.013), SDSC ( p < 0.001), and SN-5 ( p < 0.001) values. Meanwhile, there was no significant difference in the F-COPES value ( p = 0.129). Conclusions The administration of HDM immunotherapy can improve the participant's immunity, quality of life, and sleep disorder.

show abstract

Section: Methodsmentioning

confidence: 99%

The role of house dust mite immunotherapy in Indonesian children with chronic rhinosinusitis allergy: A randomized control trial

Putera

Hikmah

Endaryanto

et al. 2021

Heliyon

View full text Add to dashboard Cite

show abstract

“…ARS is characterized by a decrease of life quality of patients with the possible development of complication (chronic RS, orbital and intracranial complications, et al) [1][2][3]. At the same time, orbital and intracranial complications are gradually increasing in severity and number [4]. In addition, ARS is a very common diagnosis, accounting for approximately 30 million primary care visits to the United States and requiring more than $ 11 billion in health care costs annually [5].…”

Section: Introductionmentioning

confidence: 99%

Some aspects of enisamium iodide nasal spray safety: pre-clinical study results

Zhulai

Зупанец

Shebeko

et al. 2020

ScienceRise: Medical Science

View full text Add to dashboard Cite

Обґрунтування безпеки використання нового назального спрею з Енісаміумом Йодидом за результатами дослідження гострої місцевоподразнювальної дії досліджуваного препарату одноразовому введенні у кон'юнктивальний мішок та носовий хід кролів. Матеріали та методи. Енісаміум Йодид 10 мг/мл (назальний спрей) був об'єктом тестування. Референтним препаратом був 0,9 % розчин натрію хлориду. Для індукції експерименту використовували кролів породи Фландр (Фламандський Гігант) (2 групи, по 9 кролів у кожній групі). Об'єкти дослідження вводили одноразово в очні кон'юнктивальні мішки (0,01 мл) та носові ходи (0,1 мл) шляхом інстиляції. Очний огляд ми проводили в різні часові точки спостереження (через 1, 24, 48 та 72 години після введення препаратів). Назальна ендоскопія застосовувалася для контролю стану слизової оболонки порожнини носа на всіх стадіях дослідження (за 15 хвилин до, 1 годину та 24 години після інстиляції лікарських засобів) під загальною анестезією. Шкала оцінки використовувалася для об'єктивності результатів. Результати. Загальний бал становив 0 балів у всіх групах у всі періоди часу спостереження за відповідною шкалою та шкалою оцінки слизової оболонки порожнини носа кролів за результатами ендоскопії носа. Це відповідає стану здорового ока та здорової слизової оболонки носа. Висновки. Енісаміум Йодид 10 мг/мл (назальний спрей) при одноразовому введенні в кон'юнктивальний мішок та носовий хід кролів не виявляв ммісцевоподразнювальної дії на кон'юнктиву ока та слизову порожнину носа у експериментальних тварин. Назальна ендоскопія може бути використана як інформативний візуальний метод у доклінічних дослідженнях Ключові слова: гостра місцевоподразнювальна дія, Енісаміум Йодид (назальний спрей), назальна ендоскопія, одноразове введення, релевантна шкала оцінки

show abstract

“…The main symptoms of AR include sneezing, stuffy nose, runny nose, and itchy nose. Several cases of AR are accompanied by the occurrence of symptoms in eyes, ears, and post nasal drip in throat 1 . The assessment of AR symptom severity is determined by total nasal symptom score (TNSS) 2 .…”

Section: Introductionmentioning

confidence: 99%

The Effectiveness Comparison of Desloratadine and Loratadine in Reducing Total Nasal Symptom Score and the Level of Interleukin 4 in the Nasal Secretions of Allergic Rhinitis Patients

2020

IJFMT

View full text Add to dashboard Cite

Background: Allergic rhinitis (AR) is a common atopic disease; however, the available therapy has limitation in the usage and its success rate. Desloratadine has a role as an alternative allergic rhinitis therapy to eliminate the overall symptoms of AR and reduce IL-4 level in nasal secretions.Method: This study was double-blind randomised clinical trial with pre-post test design. The data was analyzed by using independent sample t-test. There were 24 AR patients divided into 2 therapy groups which were study group (desloratadine) and control group (loratadine). The evaluation based on SGHT and IL-4 in nasal secretions was conducted pre and post 15 days of therapy.Results: The present study that was conducted on July-October 2016 showed significant difference in the average percentage of reduced TNSS in desloratadine group compared to loratadine group (p=0.000). The comparison of reduced level of IL-4 in nasal secretions between desloratadine and loratadine group was indicated insignificantly different. Conclusion:Reduced TNSS in desloratadine group was higher than in loratadine group. Also, there was no difference in decreased level of IL-4 in nasal secretions.

show abstract

Correlation Between Objective Evaluation Result of Nasal Congestion and Life Quality in Patients with Acute Rhinosinusitis

Cited by 5 publications

References 15 publications

The role of house dust mite immunotherapy in Indonesian children with chronic rhinosinusitis allergy: A randomized control trial

The role of house dust mite immunotherapy in Indonesian children with chronic rhinosinusitis allergy: A randomized control trial

Some aspects of enisamium iodide nasal spray safety: pre-clinical study results

The Effectiveness Comparison of Desloratadine and Loratadine in Reducing Total Nasal Symptom Score and the Level of Interleukin 4 in the Nasal Secretions of Allergic Rhinitis Patients

Contact Info

Product

Resources

About